| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Mogroside IV-E targets pathways involved in metabolism, inflammation, and cell proliferation. Like other mogrosides, it exhibits antidiabetic, antioxidant, and anticancer activities. Its mechanism of action is believed to involve the modulation of AMPK and other metabolic regulators, similar to its aglycone, Mogrol. It has been shown to inhibit the proliferation of HT29 and Hep-2 cells.
|
|---|---|
| ln Vitro |
In vitro, Mogroside IV-E demonstrates significant biological activity. It inhibits the proliferation of HT29 and Hep-2 cells in culture in a dose-dependent manner. This activity is accompanied by its antioxidant properties. As a nonsugar sweetener, it provides sweetness without the caloric load of sucrose, and its bioactivity makes it a compound of interest for metabolic and cancer research.
|
| ln Vivo |
In vivo, Mogroside IV-E has shown efficacy in xenografted mice, where it inhibits the proliferation of HT29 and Hep-2 cells in a dose-dependent manner. This suggests it has antitumor activity in vivo. Its antidiabetic and antioxidant effects are also believed to contribute to its overall health benefits. Further studies are needed to fully characterize its in vivo pharmacology.
|
| Enzyme Assay |
The in vitro cell proliferation assay is the primary method for evaluating Mogroside IV-E's activity. Cancer cell lines, such as HT29 (colon cancer) and Hep-2 (laryngeal cancer), are cultured in 96-well plates and treated with varying concentrations of the compound. After 48-72 hours of incubation, cell viability is assessed using a standard colorimetric assay like MTT or SRB, from which the IC50 value is determined.
|
| Cell Assay |
In vitro cell culture studies for Mogroside IV-E involve detailed mechanistic investigations. Treated cancer cells are analyzed for apoptosis using Annexin V/PI staining and flow cytometry. Cell cycle distribution is assessed by propidium iodide staining. The expression of proteins involved in cell survival, proliferation, and metabolism, such as AMPK and its downstream targets, can be analyzed by Western blotting to confirm the mechanism of action.
|
| Animal Protocol |
In vivo animal experiments for Mogroside IV-E have been performed in xenograft models. Immunodeficient mice are implanted with human tumor cells, such as HT29 or Hep-2 cells. Once tumors are established, Mogroside IV-E is administered. Tumor growth is monitored over time, and at the end of the study, tumors are excised and analyzed for histopathology and molecular markers.
|
| ADME/Pharmacokinetics |
Mogroside IV-E has a molecular formula of C54H92O24 and a molecular weight of 1125.29 g/mol. It is a solid compound that is soluble in water and organic solvents like DMSO. As a glycoside, it is more polar than its aglycone. It is typically stored as a powder at -20°C for long-term stability. Its stability is maintained under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for Mogroside IV-E are limited, as it is a research compound. As a natural sweetener from monk fruit, it is generally recognized as safe for human consumption at dietary levels. However, as a research compound, it is not intended for therapeutic use, and comprehensive toxicity studies are not available. Standard safety precautions should be followed.
|
| References | |
| Additional Infomation |
Reports indicate that Siamese marigold (Siraitia siamensis) and Grosvenorii (Siraitia grosvenorii) contain Mogrol IVe, and relevant data is available for reference.
Mogroside IV-E is a research compound with no clinical approval. It is a valuable tool for studying the pharmacology of mogrosides and their potential applications in diabetes, cancer, and metabolic diseases. Its sweetening properties and bioactivity make it a compound of interest for the development of functional foods and nutraceuticals. |
| Molecular Formula |
C54H92O24
|
|---|---|
| Molecular Weight |
1125.2939
|
| Exact Mass |
1124.597
|
| CAS # |
88915-64-4
|
| PubChem CID |
102004786
|
| Appearance |
White to off-white solid powder
|
| Density |
1.46±0.1 g/cm3
|
| Boiling Point |
1179.3±65.0 °C at 760 mmHg
|
| Flash Point |
667.0±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.632
|
| LogP |
1.4
|
| Hydrogen Bond Donor Count |
16
|
| Hydrogen Bond Acceptor Count |
24
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
78
|
| Complexity |
2030
|
| Defined Atom Stereocenter Count |
30
|
| SMILES |
C[C@H](CC[C@H](C(C)(C)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)[C@H]3CC[C@@]4([C@@]3(C[C@H]([C@@]5([C@@H]4CC=C6[C@H]5CC[C@@H](C6(C)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)O)C)O)C)C
|
| InChi Key |
WRPAFPPCKSYACJ-KGFBLRRZSA-N
|
| InChi Code |
InChI=1S/C54H92O24/c1-22(9-13-33(51(4,5)70)77-49-45(41(66)36(61)28(20-57)74-49)78-48-44(69)39(64)35(60)27(19-56)73-48)23-15-16-52(6)30-12-10-24-25(54(30,8)31(58)17-53(23,52)7)11-14-32(50(24,2)3)76-47-43(68)40(65)37(62)29(75-47)21-71-46-42(67)38(63)34(59)26(18-55)72-46/h10,22-23,25-49,55-70H,9,11-21H2,1-8H3/t22-,23-,25-,26-,27-,28-,29-,30-,31-,32+,33-,34-,35-,36-,37-,38+,39+,40+,41+,42-,43-,44-,45-,46-,47+,48+,49+,52+,53-,54+/m1/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R,6R)-6-[[(3S,8R,9R,10R,11R,13R,14S,17R)-17-[(2R,5R)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-hydroxy-6-methylheptan-2-yl]-11-hydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~88.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8887 mL | 4.4433 mL | 8.8866 mL | |
| 5 mM | 0.1777 mL | 0.8887 mL | 1.7773 mL | |
| 10 mM | 0.0889 mL | 0.4443 mL | 0.8887 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
